Final answer:
To correct coagulopathy in uremic patients, agents such as desmopressin, conjugated estrogen, and hemodialysis may be used, each addressing different aspects of impaired coagulation and managing bleeding risks.
Step-by-step explanation:
The agent used to correct coagulopathy in uremic patients is frequently a compound known as desmopressin (DDAVP). Desmopressin is a synthetic analogue of the hormone vasopressin. It acts by increasing the release of von Willebrand factor and factor VIII, which are crucial components involved in blood clotting. It is also used to decrease the risk of hemorrhage associated with surgery or invasive procedures in these patients.
Another treatment option includes conjugated estrogen, which can improve platelet function and help control bleeding related to coagulopathy. Additionally, hemodialysis is important for removing waste products and excess fluid from the blood, which can help mitigate some of the conditions that contribute to uremic coagulopathy.
In some cases, transfusions of platelets or fresh frozen plasma may be needed to correct the coagulopathy if medical therapy is not sufficient.